Conferences - Results from #40

Viewing 41-60 of 11487 articles

SNMMI 2024: PSMA RLT- To Combine or Not to Combine

SNMMI 2024: Update from the PSMA-dRT Trial: A Randomized Phase III Trial of PSMA-PET/CT Prior to Definitive Radiation Therapy for Unfavorable Intermediate-risk or High-risk Prostate Cancer

SNMMI 2024: 18F-rhPSMA-7 and 18F-flotufolastat PET-guided Salvage Radiotherapy in Recurrent Prostate Cancer

SNMMI 2024: The Tumor Sink Effect on PSMA-PET/CT in Metastatic Prostate Cancer and its Implications for PSMA-RLT: Insight from the 3TMPO Study

AMA 2024: 2024 American Medical Association Annual House of Delegates Meeting Primer

ASCO 2024: What Is Variant Histology Renal Cell Cancer and What Are the Available Treatment Options?

ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options?

ASCO 2024: Using Artificial Intelligence to Optimize Systemic Therapy for Prostate Cancer

ASCO 2024: Artificial Intelligence and Deep Learning in Prostate Cancer Pathology

ASCO 2024: Artificial Intelligence: Innovation and Potential for Diagnostic Imaging in Prostate Cancer

ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

ASCO 2024: FGFR3 Alterations in Patients Who Develop Locally Advanced or Metastatic Urothelial Cancer, and Their Association with Tumor Subtype and Clinical Outcomes in Patients Treated with Erdafitinib Versus Pembrolizumab

ASCO 2024: Cost-Effectiveness Analysis of Contemporary First-Line Agents in Locally Advanced/metastatic Urothelial Carcinoma

ASCO 2024: Considerations in Treating and Palliating Variant Genitourinary Cancers Where No Standard of Care Exists

ASCO 2024: Age and Other Criteria Influencing Non-Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries

ASCO 2024: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC

ASCO 2024: Avelumab First Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Histological Subtypes

ASCO 2024: Prognostic Impact of Residual Cancer Burden on Long-Term Outcomes After Neoadjuvant Androgen Receptor Pathway Inhibitor and Radical Prostatectomy for High-Risk Localized Prostate Cancer: A Pooled Analysis of Phase 2 Trials

ASCO 2024: Patient-Centered Approaches to Improve Quality of Life and Mitigate the Adverse Effects of Androgen Deprivation Therapy

ASCO 2024: Debunking the Frailty-Sarcopenia-ADT Axis in Metastatic Prostate Cancer with Multicomponent Exercise: The FIERCE Trial

1
2
3
4
5
6
7
8
9
10